Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by stanleyon Oct 11, 2012 6:45pm
275 Views
Post# 20475459

Brigus Arranges $10-million Private Placement

Brigus Arranges $10-million Private Placement

 

Brigus Arranges $10-million Private Placement

2012-10-11 16:36 ET - News Release

 

Ms. Jennifer Nicholson reports

BRIGUS GOLD CORP. ANNOUNCES BOUGHT DEAL PRIVATE PLACEMENT OF FLOW-THROUGH SHARES

Brigus Gold Corp. has entered into an agreement with a syndicate of underwriters led by Cormark Securities Inc. and including Haywood Securities Inc., Fraser Mackenzie Ltd., Primary Capital Inc. and Casimir Capital Ltd., pursuant to which the underwriters have agreed to act in connection with the offer and sale of 8,264,500 flow-through shares of Brigus on a private placement basis. The flow-through shares shall be offered at a price of $1.21 per share for aggregate gross proceeds of approximately $10.0-million.

The closing of the offering is expected to occur on or about Nov. 1, 2012, and is subject to the completion of formal documentation and receipt of regulatory approval, including the approval of the Toronto Stock Exchange.

The proceeds received by the company from the sale of the flow-through shares will be used to incur Canadian exploration expenditures that are flow-through mining expenditures (as such terms are defined in the Income Tax Act (Canada)) on the corporation's properties in the province of Ontario, which will be renounced to the subscribers with an effective date no later than Dec. 31, 2012, in the aggregate amount of not less than the total amount of the gross proceeds raised from the issue of flow-through shares. The funds are intended to be used to explore areas within the Black Fox complex in the Timmins gold district of Ontario, Canada.

We seek Safe Harbor.

Bullboard Posts